Evidence map›Paper›PMID 34307428›Full record

ArticleFrontiers in medicine2021

Suboptimal Response to Tenofovir Alafenamide in Two Patients With HBeAg-Positive Hepatitis B: A Case Report.

Ruochan Chen, Siya Pei, Yayu Chen, Linxia Tan, Ying Xue, Shao Liu, Yan Huang, Xuegong Fan

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Ruochan ChenDepartment of Infectious Disease, Xiangya Hospital, Central South University, Changsha, China.
Siya PeiDepartment of Infectious Disease, Xiangya Hospital, Central South University, Changsha, China.
Yayu ChenDepartment of Infectious Disease, Xiangya Hospital, Central South University, Changsha, China.
Linxia TanDepartment of Infectious Disease, Xiangya Hospital, Central South University, Changsha, China.
Ying XueDepartment of Pharmacy, Xiangya Hospital, Central South University, Changsha, China.
Shao LiuDepartment of Pharmacy, Xiangya Hospital, Central South University, Changsha, China.
Yan HuangDepartment of Infectious Disease, Xiangya Hospital, Central South University, Changsha, China.
Xuegong FanDepartment of Infectious Disease, Xiangya Hospital, Central South University, Changsha, China.
Central South University · CNXiangya Hospital Central South University · CNHunan Academy of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tenofovir alafenamide (TAF) is one of the most potent first-line nucleot(s)ide analogs for treating chronic hepatitis B virus (HBV) infections. To date, no cases of TAF drug resistance and/or suboptimal response have been reported. To our knowledge, this is the first report of two adult male patients presenting a suboptimal response response to TAF monotherapy. Our study indicates long-term observations and extensive data are needed to further evaluate the efficacy and safety of TAF, and highlights the need for the development of robust novel direct-acting antivirals and immune therapies for HBV.

Indexed as

case reportHBeAg-positive chronic hepatitis Bmonotherapysuboptimal responsetenofovir alafenamide

Identifiers

PMID34307428
PMCPMC8295557
OpenAlexW3183018415

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.